Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning

Cancer Cell International

Volumn 11, Issue , 2011, Pages

  Milane, Lara ^a   Duan, Zhenfeng ^b   Amiji, Mansoor ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CELL MARKER; GLUCOSE TRANSPORTER 1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYPOXIA INDUCIBLE FACTOR; LACTATE DEHYDROGENASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CANCER SURGERY; CELL HYPOXIA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GLYCOLYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEIC ACID ANALYSIS; ORTHOTOPIC TRANSPLANTATION; OVARY CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 79851509477     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-11-3     Document Type: Article

References (55)

1. Harris AL, Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta oncologica (Stockholm, Sweden) 1992, 31(2):205-213. 10.3109/02841869209088904, 1352455.
2. Jamroziak K, Robak T. Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology (Amsterdam, Netherlands) 2004, 9(2):91-105.
3. Leighton JC, Goldstein LJ. P-glycoprotein in adult solid tumors. Expression and prognostic significance. Hematology/oncology clinics of North America 1995, 9(2):251-273.
4. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. Journal of the National Cancer Institute 2007, 99(19):1441-1454. 10.1093/jnci/djm135, 17895480.
5. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer science 2003, 94(1):15-21. 10.1111/j.1349-7006.2003.tb01345.x, 12708468.
6. Yague E, Arance A, Kubitza L, O'Hare M, Jat P, Ogilvie CM, Hart IR, Higgins CF, Raguz S. Ability to acquire drug resistance arises early during the tumorigenesis process. Cancer research 2007, 67(3):1130-1137. 10.1158/0008-5472.CAN-06-2574, 17283147.
7. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature reviews 2002, 2(1):48-58. 10.1038/nrc706, 11902585.
8. Chinn LW, Kroetz DL. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clinical pharmacology and therapeutics 2007, 81(2):265-269. 10.1038/sj.clpt.6100052, 17259950.
9. Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochimica et biophysica acta 2007, 1775(2):237-262.
10. Kimura Y, Morita S, Matsuo M, Ueda K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer science 2007, 98(9):1303-1310. 10.1111/j.1349-7006.2007.00538.x, 17608770.
11. Buys TP, Chari R, Lee EH, Zhang M, MacAulay C, Lam S, Lam WL, Ling V. Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells. Genes, chromosomes & cancer 2007, 46(12):1069-1079.
12. Lemos C, Jansen G, Peters GJ. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. British journal of cancer 2008, 98(5):857-862. 10.1038/sj.bjc.6604213, 2266858, 18253130.
13. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat 2007, 10(1-2):59-67. 10.1016/j.drup.2007.02.002, 17350322.
14. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E, Los M. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 2007, 10(1-2):13-29. 10.1016/j.drup.2007.01.003, 17303468.
15. Mimeault M, Hauke R, Batra SK. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clinical pharmacology and therapeutics 2008, 83(5):673-691. 10.1038/sj.clpt.6100296, 2839198, 17786164.
16. Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 2006, 4(2):61-70. 10.1158/1541-7786.MCR-06-0002, 16513837.
17. Guppy M. The hypoxic core: a possible answer to the cancer paradox. Biochemical and biophysical research communications 2002, 299(4):676-680. 10.1016/S0006-291X(02)02710-9, 12459193.
18. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Seminars in radiation oncology 2004, 14(3):198-206. 10.1016/j.semradonc.2004.04.008, 15254862.
19. Campbell RB, Ying B, Kuesters GM, Hemphill R. Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. Journal of pharmaceutical sciences 2009, 98(2):411-429. 10.1002/jps.21458, 18563780.
20. Preise D, Mazor O, Koudinova N, Liscovitch M, Scherz A, Salomon Y. Bypass of tumor drug resistance by antivascular therapy. Neoplasia (New York, NY) 2003, 5(6):475-480.
21. Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anti-cancer agents in medicinal chemistry 2008, 8(7):790-797.
22. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nature reviews 2002, 2(1):38-47. 10.1038/nrc704, 11902584.
23. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell death and differentiation 2008, 15(4):678-685. 10.1038/cdd.2008.21, 18259193.
24. Semenza GL. Targeting HIF-1 for cancer therapy. Nature reviews 2003, 3(10):721-732. 10.1038/nrc1187, 13130303.
25. Depping R, Steinhoff A, Schindler SG, Friedrich B, Fagerlund R, Metzen E, Hartmann E, Kohler M. Nuclear translocation of hypoxia-inducible factors (HIFs): involvement of the classical importin alpha/beta pathway. Biochimica et biophysica acta 2008, 1783(3):394-404. 10.1016/j.bbamcr.2007.12.006, 18187047.
26. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. Journal of molecular medicine (Berlin, Germany) 2007, 85(12):1301-1307.
27. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. Journal of the National Cancer Institute 2001, 93(4):266-276. 10.1093/jnci/93.4.266, 11181773.
28. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. Cancer science 2003, 94(12):1021-1028. 10.1111/j.1349-7006.2003.tb01395.x, 14662015.
29. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer treatment reviews 2003, 29(4):297-307. 10.1016/S0305-7372(03)00003-3, 12927570.
30. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. Induction of HIF-1alpha in response to hypoxia is instantaneous. Faseb J 2001, 15(7):1312-1314.
31. Nanduri J, Yuan G, Kumar GK, Semenza GL, Prabhakar NR. Transcriptional responses to intermittent hypoxia. Respiratory physiology & neurobiology 2008, 164(1-2):277-281.
32. Semenza GL. Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB life 2008, 60(9):591-597. 10.1002/iub.93, 18506846.
33. Liu H, Savaraj N, Priebe W, Lampidis TJ. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochemical pharmacology 2002, 64(12):1745-1751. 10.1016/S0006-2952(02)01456-9, 12445863.
34. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. The Journal of biological chemistry 2002, 277(26):23111-23115. 10.1074/jbc.M202487200, 11943784.
35. Lum JJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, Simon MC, Thompson CB. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes & development 2007, 21(9):1037-1049.
36. Robey IF, Lien AD, Welsh SJ, Baggett BK, Gillies RJ. Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia (New York, NY) 2005, 7(4):324-330.
37. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis?. Nature reviews 2004, 4(11):891-899. 10.1038/nrc1478, 15516961.
38. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochemical pharmacology 2002, 64(5-6):993-998. 10.1016/S0006-2952(02)01168-1, 12213597.
39. Lopez-Lazaro M. The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen?. Anti-cancer agents in medicinal chemistry 2008, 8(3):305-312. 10.2174/187152008783961932, 18393789.
40. Seagroves TN, Ryan HE, Lu H, Wouters BG, Knapp M, Thibault P, Laderoute K, Johnson RS. Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol 2001, 21(10):3436-3444. 10.1128/MCB.21.10.3436-3444.2001, 100265, 11313469.
41. Semenza GL. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. Journal of bioenergetics and biomembranes 2007, 39(3):231-234. 10.1007/s10863-007-9081-2, 17551816.
42. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004, 84(6):1014-1020. 10.1016/j.ygeno.2004.08.010, 15533718.
43. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134(5):703-707. 10.1016/j.cell.2008.08.021, 18775299.
44. Warburg O. On respiratory impairment in cancer cells. Science (New York, NY) 1956, 124(3215):269-270.
45. Young CD, Anderson SM. Sugar and fat - that's where it's at: metabolic changes in tumors. Breast Cancer Res 2008, 10(1):202. 10.1186/bcr1852, 2374962, 18304378.
46. Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer cell 2006, 10(3):175-176. 10.1016/j.ccr.2006.08.015, 16959608.
47. Pedersen PL. Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen. Journal of bioenergetics and biomembranes 2007, 39(3):211-222. 10.1007/s10863-007-9094-x, 17879147.
48. Ellison G, Klinowska T, Westwood RF, Docter E, French T, Fox JC. Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 2002, 55(5):294-299. 10.1136/mp.55.5.294, 1187258, 12354931.
49. Cuezva JM, Ortega AD, Willers I, Sánchez-Cenizo L, Aldea M, Sánchez-Aragó M. The tumor suppressor function of mitochondria: Translation into the clinics. Biochimica et Biophysica Acta - Molecular Basis of Disease 2009, 1792(12):1145-1150.
50. Smaldone MC, Maranchie JK. Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urologic oncology 2009, 27(3):238-245.
51. Ohta S. Contribution of somatic mutations in the mitochondrial genome to the development of cancer and tolerance against anticancer drugs. Oncogene 2006, 25(34):4768-4776. 10.1038/sj.onc.1209602, 16892089.
52. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25(34):4633-4646. 10.1038/sj.onc.1209597, 16892078.
53. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer cell 2009, 15(3):232-239. 10.1016/j.ccr.2009.01.021, 19249681.
54. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer cell 2009, 15(3):167-170. 10.1016/j.ccr.2009.02.007, 19249675.
55. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15(3):220-231. 10.1016/j.ccr.2009.01.027, 2874829, 19249680.